Regulatory Science of Complex Generics: Q3 Characterization and Bioequivalence

RAHIBA K V; HRIDHYA M; MOHAMED SHAMEER KP; SONA FATHIMA S; V A ANSHILA

Regulatory Science of Complex Generics: Q3 Characterization and Bioequivalence

Author(s)	Ms. RAHIBA K V, Ms. HRIDHYA M, Mr. MOHAMED SHAMEER KP, Ms. SONA FATHIMA S, Ms. V A ANSHILA
Country	India
Abstract	Complex generic drug products occupy an increasingly important space between conventional small-molecule generics and highly complex biological medicines [1,2]. Their equivalence cannot always be demonstrated adequately by a simple comparison of active ingredient content and systemic exposure because formulation structure, microarchitecture, drug distribution, release behavior, and manufacturing history may materially influence performance [1,2]. This review examines a regulatory-science framework that links qualitative and quantitative composition (Q1/Q2), physicochemical and structural characterization (Q3), in-vitro performance, and bioequivalence evidence for complex generics [3,4]. Particular attention is given to topical semisolids, long-acting injectable products, liposomal and other non-biological complex drugs, because these classes illustrate different mechanisms by which formulation and process variables can affect critical quality attributes and clinical performance [5–8]. Recent regulatory developments are considered alongside scientific literature, with emphasis on the evolving use of comparative Q3 characterization, in-vitro release testing, in-vitro permeation testing, pharmacokinetic approaches, and model-informed evidence [9–12]. The review also considers Quality by Design as a framework for linking material attributes and process parameters to critical quality attributes and regulatory control strategies [13,14]. A comparative perspective on the United States and European regulatory environments highlights areas of convergence as well as remaining differences in evidentiary expectations [15,16]. The review proposes an integrated, risk-based evidence model in which no single analytical test is assumed to establish equivalence for every complex product [1,2]. Instead, orthogonal characterization and performance data should be combined according to the product’s mechanism, route of administration, critical quality attributes, and residual uncertainty [1,2]. Such an approach may improve scientific consistency, reduce unnecessary clinical burden, and support development of high-quality generic alternatives [1,2].
Keywords	complex generics; bioequivalence; Q3 characterization; critical quality attributes; in vitro release; in-vitro permeation; regulatory science; Quality by Design; non-biological complex drugs.
Field	Medical / Pharmacy
Published In	Volume 8, Issue 5, September-October 2026
Published On	2026-09-26

View / Download PDF File

About IJFMR Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us		+91-9687-828-838	editor@ijfmr.com

International Journal For Multidisciplinary Research

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Regulatory Science of Complex Generics: Q3 Characterization and Bioequivalence

Share this